si esta prohibida y en europa tambien el enlace es del 2000, pero sigue igual por eso dan por supuesto ke lo llevan clarinete con poder vender en europa
digamos ke la fda es mas permisiva en aprobar algo aunke tenga contraidicaciones( tendra mucho falmialiar abogado allie n usa jajaja) , en cambio a la ema no le importa tanto si es mas o menso efectivo le imorporta ke no sea dañino.
es decir arna lo tiene facil en europa y vvus lo tiene muyyy negro
Es por estar mas cerca de las Serebro mas que nada... bueno y también se me acaba la visa...
Si alguien aun aguanta EXEL( como yo) .
Exelixis Announces August 2nd Webcast of Second Quarter 2012 Financial Results Conference Call
July 19, 2012 04:18 PM Eastern Daylight Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) will release its second quarter 2012 financial results on Thursday, August 2, 2012, after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EDT/ 2:00 p.m. PDT. During the webcast, Exelixis management will discuss the Company’s financial results, financial outlook and development program and plans for cabozantinib, and also provide a general business update. The webcast may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.
An archived replay of the webcast will be available on the Event Calendar page under Investors at http://www.exelixis.com and via phone until 11:59 p.m. PDT on September 2, 2012. Access numbers for the phone replay are: 888-286-8010 (domestic) and 617-801-6888 (international); the passcode is 13635336.
About Exelixis
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib (XL184), its most advanced product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, broadly-active, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at http://www.exelixis.com.
si las pillaste antes del ASCO las debes tener ya en +20-25%, no?
EXEL
Compradas a 4,51, creo que las aguamtaré un poco mas.
Pienso que Prometeo tb llevaba de esta.
SI, se quito de encima la mitad, pero mantuvo el resto.
Pero yo llevo poca carga 1200 : (
GNOM ,defender enérgicamente contra demanda por infracción de patentes.
http://www.globenewswire.com/newsroom/news.html?d=259746
Complete Genomics, Inc. to Vigorously Defend Against Patent Infringement Suit
MOUNTAIN VIEW, Calif., June 19, 2012 (GLOBE NEWSWIRE) -- Complete Genomics, Inc. (Nasdaq:GNOM), announced today that it intends to vigorously defend itself against the patent infringement suit recently filed by Illumina, Inc. in the U.S. District Court for the Southern District of California. The complaint alleges that Complete infringes a single Illumina patent relating to a "Method for Sequencing a Polynucleotide Template." Complete considers the lawsuit to be wholly without merit.
"Despite this move by Illumina, we remain fully committed to the strategy and actions that we recently announced," stated Dr. Clifford A. Reid, Ph.D., Complete's chairman, president and chief executive officer. "We will continue to fully service and support our customers while defending against this lawsuit. This is yet another attempt by Illumina to compete in the courtroom instead of the marketplace and reflects the extent to which it sees Complete's more accurate genome sequencing technology as a competitive threat."
In August 2010, Illumina sued Complete for infringement of another patent, in a case now pending in the U.S. District Court for the Northern District of California. Complete considers that suit to also be without merit and recently filed a motion for summary judgment setting forth numerous grounds for the patent in issue being declared invalid.
About Complete Genomics
Complete Genomics is the whole human genome sequencing company that has developed and commercialized an innovative DNA sequencing platform. The Complete Genomics Analysis Platform (CGA™ Platform) combines proprietary human genome sequencing technology with advanced informatics and data management software. Additional information can be found at www.completegenomics.com.
Caution Regarding Forward-Looking Statements
This Press Release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, including statements regarding the Complete Genomics, Inc. intention to defend itself against the lawsuits brought against it by Illumina, Inc. These forward-looking statements are based on management's current expectations, are not guarantees of future performance, and involve certain risks and uncertainties that could cause actual results to differ materially from management's current expectations and these forward-looking statements. These risks and uncertainties include, but are not limited to, the complexities, expense and unpredictability of litigation, and other risks detailed in the company's most recent Annual Report on Form 10-K, filed with the SEC on March 9, 2012, and Quarterly Report on Form 10-Q, filed with the SEC on May 9, 2012. The company disclaims any obligation to update information contained in its forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Complete Genomics, Inc.
Scott Sandler
Investor Relations
(650) 943-2788
[email protected]
